What happens if you inject a degraded peptide?
Last updated: October 27, 2026 · 9 min read · By the Grey Peptides Editorial Board
- Heat, light and time break peptides into altered forms, and some of those forms clump together.
- Clumped protein is unusually good at provoking antibodies, which can cost a drug its effect, neutralise the body's own version of the molecule or cause allergy.
- With licensed medicines this has caused real harm, including a rare blood disorder after antibodies to an anaemia drug.
- Approved peptide products carry strict storage limits, written into their labels. Research vials come with no approved label at all.
What degradation actually is
A peptide is a chain of amino acids held in a particular shape, and heat and light change it. A 2025 study exposed synthetic liraglutide to heat and light and identified ten impurities, four of them not previously reported, mapping where on the chain each change occurred; its authors note that peptides are prone to degradation, particularly under improper storage or handling, and that such impurities may compromise a drug's quality and safety (laboratory study) 1. Impurities are present even in a pharmacopoeia reference standard: an analysis of China's thymalfasin standard separated 23 related impurities above 0.1 mg/g, including deamination, succinimide and dimer forms, more than half of them arising directly or indirectly from one labile asparagine at the end of the chain (laboratory study) 2.
| What happens | Why it matters |
|---|---|
| Chemical change (oxidation, deamidation, breakage) | Creates impurities, molecules slightly different from the intended peptide, that may compromise the drug's quality and safety |
| Aggregation (clumping) | Repeating, arrayed structures are potent at provoking antibodies |
| Anti-drug antibodies | Can cause loss of effect, neutralise the body's own version of the molecule, or cause allergic reactions |
| Local deposits | Insulin forms lumps at injection sites that reduce absorption by 27% to 94% |
Why clumping matters most
Aggregation means clumping into larger assemblies. A 2006 review by an FDA scientist explains that the ability of protein aggregates to boost immune responses against the normal form of the protein has been known for more than half a century, and connects aggregates to antibody-mediated adverse events with early therapeutic proteins such as intravenous immune globulin and human growth hormone. Proteins presented in a highly repeating, arrayed structure, as in large aggregates, are potent inducers of antibodies even without T-cell help, and the review suggests this may be because the repeating pattern extensively cross-links receptors on antibody-producing B cells (review) 3.
A 2005 review lists the factors that influence immunogenicity of therapeutic proteins: structural features, storage conditions (denaturation, or aggregation caused by oxidation), contaminants and impurities, dose and length of treatment, route of administration, formulation and the patient's own genetics (review) 4. Storage conditions and impurities are the factors on that list a mishandled vial can change.
What antibodies do
The 2005 review lists what antibodies against a therapeutic protein can do: cost the drug its effect, neutralise the body's own version of the molecule, and cause general immune effects including allergy, anaphylaxis or serum sickness (review) 4.
Both antibodies and their effects appear in approved medicines. The Wegovy label reports that during 68-week treatment periods in two adult trials, 3% of patients treated with semaglutide 2.4 mg developed anti-semaglutide antibodies, and 56% of those developed antibodies that cross-reacted with the body's own GLP-1; with a newer assay, 15.4% of patients on 7.2 mg and 11.2% on 2.4 mg developed antibodies over 72 weeks in later trials. In its adult weight-reduction trials, allergic reactions occurred in 16% (8 of 50) of patients with anti-semaglutide antibodies against 7% of those without (drug label) 5.
The cautionary case is epoetin, a protein drug for anaemia. From 1998, cases of antibody-mediated pure red cell aplasia, in which red cell production stops, were reported, and causation was attributed to formulations without human serum albumin, injection under the skin and uncoated rubber stoppers; after regulators required intravenous use in dialysis patients and the maker coated its syringe stoppers, cases fell by 90% (review of regulatory and manufacturer data) 6. The 2005 review adds that the product's immunogenic potential may have been enhanced by the way it was stored, handled and administered (review) 4. It is a protein, not a small peptide, and the circumstances were specific, but it shows what formulation and handling can cost.
Lumps at the injection site
Peptides can also aggregate where they are injected. Insulin-derived amyloidosis is a skin complication of insulin treatment in which insulin forms amyloid deposits under the skin. A 2024 systematic review of 44 papers covering 127 insulin-treated patients found the abdominal wall was the commonest site, described impaired insulin absorption, and stressed proper rotation of injection sites (systematic review) 7; a scoping review found absorption at affected sites was 27% to 94% lower than at normal sites, with greater reduction where the lump could be felt (scoping review) 8.
The practical lesson is the same one our injection reactions guide gives: rotate sites, and have an unexplained lump looked at by a clinician rather than injecting into it, since absorption there is reduced 8.
What the labels require
Approved peptide products carry storage rules in their labels. The Wegovy label requires refrigeration at 2 to 8 °C for its single-dose pen, allows up to 28 days at 8 to 30 °C before the cap is removed, says to protect it from light and keep it in its carton, and says not to freeze it or use it if it has been frozen (drug label) 5. Our travel guide lists these limits for several products.
Research peptides come with no approved label. Freeze-drying them to a powder is a stability decision rather than a convenience: proteins' limited physical and chemical stability often forces a solid form to achieve an acceptable shelf life, and even solid proteins may have limited long-term stability (review) 9. Our shelf-life guide and reconstitution guide cover handling, and our bacteriostatic water guide covers the diluent.
Why injection under the skin matters
Route matters, though not simply. The epoetin review attributed the pure red cell aplasia cases partly to injection under the skin rather than into a vein, alongside a formulation change and uncoated rubber stoppers (review) 6, and the review of immunogenicity factors lists route of administration among the drivers, while noting that the under-the-skin route does not confer immunogenicity by itself (review) 4.
Repeated dosing and time
Immunogenicity also depends on how long and how often something is given. The 2005 review lists dose and length of treatment among the determinants, and notes that immune responses arise especially with multiple doses over prolonged periods 4; antibody rates in the semaglutide trials were measured over 68- and 72-week treatment periods 5.
Can you tell by looking?
Only sometimes. The Wegovy label says to inspect each injection and use it only if the solution is clear, colourless and free of particles, and to throw a pen away if it has been frozen, exposed to light or to temperatures above 30 °C, or kept out of the refrigerator for 28 days or longer (drug label) 5. But some of the changes that matter are invisible: the liraglutide stress study needed liquid chromatography and high-resolution mass spectrometry to find them 1. A clear solution is not evidence that a peptide is intact.
Why this is worse for research peptides
Research peptides carry every risk in this article with fewer checks. Their starting impurity profile is unverified; our guide to how peptides are made covers what certificates do and do not show. FDA has stated immunogenicity, peptide-related impurity and characterisation concerns for two peptides nominated for compounding, thymosin alpha-1 and LL-37, and says the safety information on thymosin alpha-1 is inadequate for it to understand the extent of any safety issues; both nominations have since been withdrawn by the nominators (FDA) 10.
Not every peptide carries the same risk
Two things temper the picture. First, the evidence here comes mostly from proteins (epoetin, immune globulin, growth hormone) and from insulin, and most of the immunogenicity literature cited concerns proteins 3 4; how strongly the same risks apply to short research peptides is not measured in these sources. Second, detecting antibodies is not the same as being harmed by them. The Wegovy label states that the clinical consequences of antibodies cross-reacting with native GLP-1 are unknown, that no clinically significant effect of anti-drug antibodies on how the body handles semaglutide was seen, and that there is insufficient evidence to characterise their effect on safety or effectiveness 5.
The honest summary is that the size of the risk for research peptides is unknown, while the chemistry that drives it is well established.
What to do with a vial you are unsure about
For an approved product, follow its label: the Wegovy label's rules are to use the solution only if clear, colourless and particle-free, to keep it in its carton out of light, and to discard it if it has been frozen, overheated or out of the refrigerator for 28 days or longer 5. Label the date of reconstitution of any vial you mix, since a solution's clock starts then, as our shelf-life guide explains. And if a product that previously worked stops working, loss of effect is one of the things antibodies can cause 4, which is a reason to talk to a clinician rather than simply raising the dose.
Questions to ask about a vial
- Has it been kept in the conditions the product's instructions specify, and for how long?
- Has it been frozen, left in a hot car or exposed to light?
- Is there visible cloudiness, particles or colour change? If so, discard it.
- Is there any batch testing for impurities and aggregates, not just purity?
- If the product stopped working, could antibodies explain it, and would anyone be able to test?
The bottom line
Heat and light create altered molecules, and clumped protein provokes antibodies unusually well. In approved medicines antibodies have meant lost effectiveness, cross-reaction with the body's own hormone, more allergic reactions, and in one well-documented case a serious blood disorder. Approved products carry strict storage limits in their labels. A research vial carries the same chemistry with no approved label.
Frequently asked questions
Is it dangerous to inject an expired peptide?
Degraded peptides can lose potency and form aggregates, and aggregated protein is unusually good at provoking antibodies. Visible changes mean discard it; invisible degradation cannot be ruled out by looking.
What are anti-drug antibodies?
Antibodies the immune system makes against an injected drug. A 2005 review lists loss of effect, neutralisation of the body's own version of the molecule and allergic reactions among their effects.
Do people get antibodies to semaglutide?
The Wegovy label reports anti-semaglutide antibodies in 3% of patients in two 68-week trials, with 56% of those cross-reacting with native GLP-1; rates differed with a newer assay.
What is an insulin ball?
Insulin-derived amyloidosis: a lump of amyloid deposits from repeated injection in one area. Insulin absorption at affected sites was 27% to 94% lower in a review.
Can I tell if a peptide has degraded by looking at it?
Cloudiness, particles or colour change mean discard it, but some changes are invisible: the impurities in a 2025 liraglutide stress study needed liquid chromatography and high-resolution mass spectrometry to find.
Related on Grey Peptides
Sources
- Badgujar, D., et al. (2025). Assessment of Thermal and Photolytic Stress Effects on the Stability of Primary Structure of Synthetic Liraglutide Using LC-HRMS/MS. J Pept Sci, 31(9), e70050. PMID: 40814845
- Cheng, Y., et al. (2022). Identification and determination of structurally related peptide impurities in thymalfasin by liquid chromatography-high-resolution mass spectrometry. Anal Bioanal Chem, 414(28), 8035-8045. PMID: 36207535
- Rosenberg, A. S. (2006). Effects of protein aggregates: an immunologic perspective. AAPS J, 8(3), E501-7. PMID: 17025268
- Schellekens, H. (2005). Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant, 20 Suppl 6, vi3-9. PMID: 15958824
- Novo Nordisk. WEGOVY (semaglutide) US prescribing information, Dosage and Administration, Adverse Reactions (Hypersensitivity), Clinical Pharmacology 12.6 (Immunogenicity), Storage and Handling and Instructions for Use. DailyMed set ee06186f, version 19, effective June 18, 2026; read October 3 and October 27, 2026. DailyMed
- McKoy, J. M., et al. (2008). Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion, 48(8), 1754-62. PMID: 18482185
- Karkhaneh, L., et al. (2024). Comprehensive investigation of insulin-induced amyloidosis lesions in patients with diabetes at clinical and histological levels: A systematic review. Diabetes Metab Syndr, 18(7), 103083. PMID: 39079306
- Ibuki, A., et al. (2023). Why and by How Much is Insulin Absorption Reduced by Insulin-derived Amyloidosis? A Scoping Review. Yakugaku Zasshi, 143(10), 865-870. PMID: 37779016
- Wang, W. (2000). Lyophilization and development of solid protein pharmaceuticals. Int J Pharm. PMID: 10967427
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (thymosin-alpha 1 and cathelicidin LL-37, both listed under nominations withdrawn by the nominators, with FDA's concerns still stated). Content current as of April 22, 2026; read October 1 and October 27, 2026. FDA
Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead